恶性疟原虫增殖的4-苯胺基喹啉抑制剂的物理化学性质优化
Optimization of Physicochemical Properties for 4-Anilinoquinoline Inhibitors of Plasmodium falciparum Proliferation.
作者信息
Mehta Naimee, Ferrins Lori, Leed Susan E, Sciotti Richard J, Pollastri Michael P
机构信息
Department of Chemistry and Chemical Biology , Northeastern University , 360 Huntington Avenue , Boston , Massachusetts 02115 , United States.
Experimental Therapeutics , Walter Reed Army Institute for Research , 2460 Linden Lane , Silver Spring , Maryland 20910 , United States.
出版信息
ACS Infect Dis. 2018 Apr 13;4(4):577-591. doi: 10.1021/acsinfecdis.7b00212. Epub 2018 Jan 17.
Abstract
We recently reported the medicinal chemistry reoptimization of a known human tyrosine kinase inhibitor, lapatinib, against a variety of parasites responsible for numerous tropical diseases, including human African trypanosomiasis ( Trypanosoma brucei), Chagas disease ( T. cruzi), Leishmaniasis ( Leishmania spp.), and malaria ( Plasmodium falciparum). Herein, we report our continuing efforts to optimize this series against P. falciparum. Through the design of a library of compounds focused on reducing the lipophilicity and molecular weight, followed by an SAR exploration, we have identified NEU-1953 (40). This compound is a potent inhibitor of P. falciparum with an improved ADME profile over the previously reported compound, NEU-961 (3).
摘要
我们最近报道了对一种已知的人类酪氨酸激酶抑制剂拉帕替尼进行药物化学再优化，以对抗多种导致众多热带疾病的寄生虫，包括人类非洲锥虫病（布氏锥虫）、恰加斯病（克氏锥虫）、利什曼病（利什曼原虫属）和疟疾（恶性疟原虫）。在此，我们报告我们针对恶性疟原虫优化该系列化合物的持续努力。通过设计一个专注于降低亲脂性和分子量的化合物库，随后进行构效关系探索，我们鉴定出了NEU-1953（40）。该化合物是一种强效的恶性疟原虫抑制剂，与先前报道的化合物NEU-961（3）相比，其药代动力学性质有所改善。
相似文献
1
Optimization of Physicochemical Properties for 4-Anilinoquinoline Inhibitors of Plasmodium falciparum Proliferation.恶性疟原虫增殖的4-苯胺基喹啉抑制剂的物理化学性质优化
ACS Infect Dis. 2018 Apr 13;4(4):577-591. doi: 10.1021/acsinfecdis.7b00212. Epub 2018 Jan 17.
2
Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation.用于锥虫增殖的4-苯胺基喹唑啉抑制剂的物理化学性质优化
Eur J Med Chem. 2017 Dec 1;141:446-459. doi: 10.1016/j.ejmech.2017.10.007. Epub 2017 Oct 6.
3
Synthesis, Plasmodium falciparum Inhibitory Activity, Cytotoxicity and Solubility of N2 ,N4 -Disubstituted Quinazoline-2,4-diamines.N2，N4-二取代喹唑啉-2,4-二胺的合成、抑制疟原虫活性、细胞毒性和溶解度。
Med Chem. 2019;15(6):693-704. doi: 10.2174/1573406415666181219100307.
4
Anilinoquinoline based inhibitors of trypanosomatid proliferation.基于吖啶酮的利什曼原虫增殖抑制剂。
PLoS Negl Trop Dis. 2018 Nov 26;12(11):e0006834. doi: 10.1371/journal.pntd.0006834. eCollection 2018 Nov.
5
Identification of novel quinazoline derivatives as potent antiplasmodial agents.鉴定新型喹唑啉衍生物作为有效的抗疟药物。
Eur J Med Chem. 2019 Jan 1;161:277-291. doi: 10.1016/j.ejmech.2018.10.041. Epub 2018 Oct 17.
6
Synthesis and in vitro antiplasmodial evaluation of 4-anilino-2-trichloromethylquinazolines.4-苯胺基-2-三氯甲基喹唑啉的合成及其体外抗疟活性评价
Bioorg Med Chem. 2009 Jul 1;17(13):4313-22. doi: 10.1016/j.bmc.2009.05.022. Epub 2009 May 15.
7
Evaluation of azasterols as anti-parasitics.氮杂甾醇作为抗寄生虫药物的评估。
J Med Chem. 2006 Oct 5;49(20):6094-103. doi: 10.1021/jm060290f.
8
4-Thiophenoxy-2-trichloromethyquinazolines display in vitro selective antiplasmodial activity against the human malaria parasite Plasmodium falciparum.4-噻吩氧基-2-三氯甲基喹唑啉对人类疟原虫恶性疟原虫表现出体外选择性抗疟原虫活性。
Bioorg Med Chem Lett. 2011 Oct 1;21(19):6003-6. doi: 10.1016/j.bmcl.2011.06.113. Epub 2011 Jul 2.
9
Exploration of a new type of antimalarial compounds based on febrifugine.基于常山碱的新型抗疟化合物的探索。
J Med Chem. 2006 Jul 27;49(15):4698-706. doi: 10.1021/jm0601809.
10
Biological characterization of chemically diverse compounds targeting the Plasmodium falciparum coenzyme A synthesis pathway.针对恶性疟原虫辅酶A合成途径的化学结构多样化合物的生物学特性研究
Parasit Vectors. 2016 Nov 17;9(1):589. doi: 10.1186/s13071-016-1860-3.
引用本文的文献
1
4-Aminoquinoline as a privileged scaffold for the design of leishmanicidal agents: structure-property relationships and key biological targets.4-氨基喹啉作为设计抗利什曼原虫药物的优势骨架：结构-性质关系及关键生物学靶点
Front Chem. 2025 Jan 29;12:1527946. doi: 10.3389/fchem.2024.1527946. eCollection 2024.
2
Looking for approved-medicines to be repositioned as anti-Trypanosoma cruzi agents. Identification of new chemotypes with good individual- or in combination-biological behaviours.寻找可重新定位为抗克氏锥虫药物的已批准药物。鉴定具有良好个体或联合生物学行为的新化学类型。
Mem Inst Oswaldo Cruz. 2025 Feb 7;120:e240183. doi: 10.1590/0074-02760240183. eCollection 2025.
3
Evolution of the Quinoline Scaffold for the Treatment of Leishmaniasis: A Structural Perspective.用于治疗利什曼病的喹啉骨架的演变：结构视角
Pharmaceuticals (Basel). 2024 Feb 22;17(3):285. doi: 10.3390/ph17030285.
4
Identification of novel anti-amoebic pharmacophores from kinase inhibitor chemotypes.从激酶抑制剂化学类型中鉴定新型抗阿米巴药效基团。
Front Microbiol. 2023 May 10;14:1149145. doi: 10.3389/fmicb.2023.1149145. eCollection 2023.
5
Structure-Bioactivity Relationships of Lapatinib Derived Analogs against .拉帕替尼衍生类似物对……的结构-生物活性关系
ACS Med Chem Lett. 2020 Jan 10;11(3):258-265. doi: 10.1021/acsmedchemlett.9b00455. eCollection 2020 Mar 12.
6
Scaffold and Parasite Hopping: Discovery of New Protozoal Proliferation Inhibitors.支架与寄生物转移：新型原生动物增殖抑制剂的发现
ACS Med Chem Lett. 2020 Jan 10;11(3):249-257. doi: 10.1021/acsmedchemlett.9b00453. eCollection 2020 Mar 12.
7
Improvement of Aqueous Solubility of Lapatinib-Derived Analogues: Identification of a Quinolinimine Lead for Human African Trypanosomiasis Drug Development.提高拉帕替尼类似物的水溶性：鉴定一种用于人类非洲锥虫病药物开发的喹啉亚胺先导化合物。
J Med Chem. 2019 Jan 24;62(2):665-687. doi: 10.1021/acs.jmedchem.8b01365. Epub 2019 Jan 10.
8
Anilinoquinoline based inhibitors of trypanosomatid proliferation.基于吖啶酮的利什曼原虫增殖抑制剂。
PLoS Negl Trop Dis. 2018 Nov 26;12(11):e0006834. doi: 10.1371/journal.pntd.0006834. eCollection 2018 Nov.
本文引用的文献
1
Repurposing strategies for tropical disease drug discovery.热带病药物研发的重新利用策略。
Bioorg Med Chem Lett. 2016 Jun 1;26(11):2569-76. doi: 10.1016/j.bmcl.2016.03.103. Epub 2016 Mar 30.
2
Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery.通过交叉筛选发现的原生动物寄生虫生长抑制剂为先导化合物发现提供了有效的骨架。
J Med Chem. 2015 Jul 23;58(14):5522-37. doi: 10.1021/acs.jmedchem.5b00515. Epub 2015 Jul 8.
3
Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax.杀死间日疟原虫的休眠子——预防间日疟复发的药物研发方法
Pathog Glob Health. 2015 May;109(3):107-22. doi: 10.1179/2047773215Y.0000000013. Epub 2015 Apr 18.
4
(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.(+)-SJ733是一种疟疾临床候选药物，它通过ATP4发挥作用，诱导宿主介导的疟原虫快速清除。
Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5455-62. doi: 10.1073/pnas.1414221111. Epub 2014 Dec 1.
5
The role of ligand efficiency metrics in drug discovery.配体效率指标在药物发现中的作用。
Nat Rev Drug Discov. 2014 Feb;13(2):105-21. doi: 10.1038/nrd4163.
6
Discovering and developing new medicines for malaria control and elimination.发现并开发用于疟疾控制与消除的新药。
Infect Disord Drug Targets. 2013 Aug;13(4):292-302. doi: 10.2174/1871526513666131129160156.
7
Antimalarial drug discovery - approaches and progress towards new medicines.抗疟药物发现——新药研发的方法和进展。
Nat Rev Microbiol. 2013 Dec;11(12):849-62. doi: 10.1038/nrmicro3138. Epub 2013 Nov 11.
8
Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis.激酶支架的重新定位用于治疗被忽视的疾病药物发现：用于锥虫病的有效、拉帕替尼衍生的先导化合物的发现。
J Med Chem. 2013 May 23;56(10):3820-32. doi: 10.1021/jm400349k. Epub 2013 May 3.
9
Recent advances in malaria drug discovery.疟疾药物发现的最新进展。
Bioorg Med Chem Lett. 2013 May 15;23(10):2829-43. doi: 10.1016/j.bmcl.2013.03.067. Epub 2013 Mar 27.
10
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.肝期疟原虫易受多种化学支架的影响。
Proc Natl Acad Sci U S A. 2012 May 29;109(22):8511-6. doi: 10.1073/pnas.1118370109. Epub 2012 May 14.
Zotero 插件